The medical education courses being developed by AusCann will enhance knowledge of the endocannabinoid system and current state of knowledge of cannabinoid therapeutics, and will include information in various forms such as online courses (including accredited for CPE), webcasts, webinars and reference material. The courses form a key component of the AusCann Medical Education Program.
Mentorship from an experienced clinician is available for Australian doctors contemplating prescription of cannabinoid medicines.
|US National Academies of Sciences, Engineering, and Medicine. 2017. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press.|
|Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington, DC: The National Academies Press. doi: https://doi.org/10.17226/24781.|
|UK All Party Parliamentary Group for Drug Reform, commissioned paper, Barnes and Barnes (2016) Cannabis: The Evidence for Medical Use|
|Moulin et al. (2014) Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society. Pain Research Management, 19(6): 328-35 Pain|
|27th Annual Symposium of the International Cannabinoid Research Society, Montreal, Canada, June 22-27, 2017 [Abstracts (8.3MB)]|
|Nielsen et al. (2017) Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. Neuropsychopharmacology, 42(9):1752-1765 [PMID: 28327548] Pain|
|Barrie et al. (2017) Endocannabinoids in arthritis: current views and perspective. International Journal of Rheumatic Disease, 20(7):789-797 [PMID: 28736968] PAIN ARTHRITIS|
|Koo CM, Kang HC (2017) Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy? Journal of Epilepsy Research, 7(1):16-20 Epilepsy|
|Haroutounian et al. (2016) The Effect of Medicinal Cannabis on Pain and Quality of Life Outcomes in Chronic Pain: A Prospective Open-label Study. Clinical Journal of Pain, 32(12): 1036-43 [PMID 26889611] Pain|
The information on this website is provided for the purpose of disseminating information pertaining to cannabinoid medicines and is targeted to health professionals, not the general public. Nothing on this website is intended to be used as medical advice and it is not intended to be used to prevent, diagnose, treat or cure any disease or condition. The information on this website has been compiled from a variety of sources and should not be considered complete. It is provided on an ‘as is’ basis, without any warranties, either express or implied
The website contains links to external sites. AusCann takes reasonable care in selecting linking websites but accepts no responsibility for material contained on an external site. It is the responsibility of the user to ensure make their own decisions regarding accuracy, currency, reliability and correctness of information on the external sites. The links are provided for convenience and do not constitute an endorsement of any third party products or services. Views put forward on third party websites do not necessarily match the views of the Company.